Adult survivors of invasive pneumococcal disease exhibit defective B cell function

Clinical Infectious Diseases

Volumn 52, Issue 9, 2011, Pages 1133-1136

  Darton, Tom C ^a,b   Wing, James B ^a   Lees, Andrew ^c   Heath, Andrew W ^a   Read, Robert C ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c Fina BioSolutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTEREMIA; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IMMUNE DEFICIENCY; MALE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SMOKING; STREPTOCOCCUS PNEUMONIAE; SURVIVOR; VACCINATION; VOLUNTEER;

ADOLESCENT; ADULT; ANTIGENS, T-INDEPENDENT; B-LYMPHOCYTES; BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 79953860250     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir126     Document Type: Article

References (14)

1. Jonsson G, Oxelius VA, Truedsson L, Braconier JH, Sturfelt G, Sjoholm AG. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J Immunol 2006; 177:722-8. (Pubitemid 43939187)
2. Ramakrishnan M, Moisi JC, Klugman KP, et al. Increased risk of invasive bacterial infections in African people with sicklecell disease: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:329-37.
3. Ku CL, Picard C, Erdos M, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 2007; 44:16-23. (Pubitemid 46142834)
4. Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Pekka Nuorti J. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008; 8:96.
5. Borrow R, Stanford E, Waight P, et al. Serotype-specific immune un-responsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease. Infect Immun 2008; 76:5305-9.
6. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198:1019-27.
7. Snapper CM, McIntyre TM, Mandler R, et al. Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med 1992; 175:1367-71.
8. Foster RA, Carlring J, McKendrick MW, et al. Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C me-ningococcal disease. Clin Vaccine Immunol 2009; 16:692-8.
9. Groth C, Drager R, Warnatz K, et al. Impaired up-regulation of CD70 and CD86 in naive (CD27-) B cells from patients with common variable immunodeficiency (CVID). Clin Exp Immunol 2002; 129: 133-9.
10. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hypores-ponsiveness an issue? Lancet Infect Dis 2007; 7:597-606. (Pubitemid 47268225)
11. Roberts J, Greenwood B, Stuart J. Sampling methods to detect carriage of Neisseria meningitidis; literature review. J Infect 2009; 58:103-7.
12. Millar EV, Watt JP, Bronsdon MA, et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008; 47:989-96.
13. Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, Makela PH. Epi-demiological evidence for serotype-independent acquired immunity to pneumococcal carriage. J Infect Dis 2009; 200:99-106.
14. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal poly-saccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6.